Leqvio (Inclisiran) Overdose and Accidental Excess Dose: What Clinicians and Patients Need to Know

Leqvio (inclisiran sodium) is a small interfering RNA (siRNA) therapy, distinct from statins, ezetimibe, and the injectable PCSK9 monoclonal antibodies evolocumab (Repatha) and alirocumab (Praluent). It is FDA-approved as an adjunct to diet and maximally tolerated statin therapy for adults with clinical atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia who need additional LDL-cholesterol lowering (FDA, approved December 2021). It is given as a 284 mg subcutaneous injection by a healthcare professional at day 0, day 90, and then every six months.

Leqvio (inclisiran sodium) is a small interfering RNA therapy administered only twice yearly by a healthcare professional, which structurally limits the opportunity for patient-driven overdose. No fatal or serious overdose has been described in the drug's published development program, and early dose-ranging studies tested doses several times higher than the approved 284 mg without a distinct toxicity signal. The FDA label states that no specific antidote exists and that management of any excess exposure is supportive. Because inclisiran's effect depends on RNA silencing that persists inside liver cells long after the injected drug clears the bloodstream, an accidental extra dose is expected to intensify and prolong LDL-C lowering rather than cause acute organ toxicity.

This article is written for clinicians managing a suspected dosing error and for patients or caregivers who want to understand what an extra or early dose means. It is not a substitute for contacting the prescribing clinician, a poison control center, or emergency services if the patient is symptomatic.

How inclisiran works, and why the mechanism shapes overdose risk

Inclisiran is conjugated to triantennary N-acetylgalactosamine (GalNAc), a sugar ligand that binds the asialoglycoprotein receptor found almost exclusively on hepatocytes. This targets the drug to the liver rather than distributing it broadly across organ systems. Inside the hepatocyte, inclisiran loads into the RNA-induced silencing complex (RISC) and degrades messenger RNA for PCSK9, a protein that normally marks LDL receptors for breakdown. With less PCSK9 made, more LDL receptors remain on the cell surface and clear more LDL cholesterol from the blood.

The parent drug has a short plasma half-life, on the order of hours, and clears from circulation quickly. The pharmacodynamic effect does not follow the same timeline. Once RISC is loaded, LDL-C lowering persists for roughly six months regardless of how much drug is still circulating. This gap between how fast the drug leaves the blood and how long its effect lasts is the central fact that should guide overdose management: there is nothing to "clear" pharmacologically once an extra dose has been given, because the relevant biology has already moved inside the cell.

What the FDA label and available trial reporting say about overdose

The Leqvio prescribing information states that there is no specific treatment for overdose and that management should be supportive. This is standard language for a drug without a reversal agent, and it does not by itself indicate that overdose is common or dangerous.

Public reporting on the ORION clinical development program describes phase 3 trials (ORION-10 and ORION-11) in which the approved 284 mg regimen produced a sustained LDL-C reduction commonly summarized as approximately 50% relative to placebo over roughly 18 months, with serious adverse events reported at similar rates between inclisiran and placebo groups. Early dose-ranging work (ORION-1) reportedly tested single and two-dose regimens at doses several-fold higher than 284 mg, up to the 800 mg range, without a distinct dose-limiting toxicity, and with injection-site reactions as the most consistently dose-related adverse effect. These are the kinds of figures most often cited for inclisiran's safety margin, but the exact percentages and event rates should be verified against the primary trial publications before being used for individual clinical decisions or restated as precise numbers in patient materials.

No published guideline from a cardiology or endocrine society specifically addresses inclisiran overdose management. The approach below is derived from the FDA label's general instruction to manage overdose supportively, combined with ordinary clinical pharmacology reasoning about the drug's mechanism.

Why a true overdose is structurally unlikely

Three design features reduce the probability of an inclisiran overdose compared with self-administered oral or injectable lipid-lowering drugs.

A clinician gives every dose. Leqvio is not dispensed to patients as a take-home supply. Each dose is a single-use prefilled syringe administered in a medical office, hospital, or infusion setting. Patients do not have access to multiple doses at home.

Each syringe is a fixed unit. There is no vial to draw from, no concentration calculation, and no infusion rate to program. Giving an unintended extra dose would require a clinician to administer more than one syringe at a single visit.

Dosing is infrequent and trackable. With only three doses in the first year and two per year afterward, most specialty pharmacy and buy-and-bill systems track administration dates. An early re-dose is more likely to be caught by scheduling systems than an error with a daily oral medication.

The realistic overdose scenario in this drug's use pattern is not a large single overdose. It is an early re-dose: a patient changes clinics, records are incomplete, and a new dose is given weeks or months ahead of the intended six-month interval, or occasionally two doses are given at the same visit in error.

What to expect after an accidental extra or early dose

Based on the drug's known pharmacology and the general shape of the dose-response data described above, the following effects are plausible after an accidental extra 284 mg dose (given as a second syringe at the same visit) or an early re-dose given weeks to a few months ahead of schedule. These are reasoned expectations, not confirmed outcomes from a dedicated overdose dataset, and should be treated as clinical judgment pending verification of the underlying trial numbers.

Deeper LDL-C lowering, with diminishing returns. The dose-response relationship for inclisiran appears to flatten well above the approved dose, so an extra dose is more likely to modestly deepen LDL-C reduction than to double it. Very low LDL-C values have been observed in large PCSK9-pathway trials without an identified safety signal, but that reassurance comes from monoclonal antibody trials (evolocumab, alirocumab), not from a dedicated inclisiran overdose dataset, and should be treated as indirect support rather than direct proof of safety at supratherapeutic inclisiran exposure.

A longer duration of effect. More siRNA loaded into hepatocyte RISC complexes may extend the LDL-lowering effect beyond the usual six months. This complicates when the next scheduled dose should be given, more than it creates acute risk.

More frequent injection-site reactions. Injection-site erythema, pain, or induration is the adverse effect most consistently linked to higher inclisiran exposure in early dose-ranging work. These reactions are typically mild and self-limiting.

No established hepatotoxicity or nephrotoxicity signal. Published summaries of the ORION program describe similar liver enzyme elevation rates between inclisiran and placebo, including at higher doses tested in early trials, and a dedicated renal pharmacokinetic study reportedly found similar drug exposure in patients with mild to moderate renal impairment compared with normal renal function. These claims should be confirmed against the primary publications before being treated as settled, but nothing in the publicly summarized data points to organ toxicity as the expected consequence of an extra dose.

Managing a suspected excess dose: a step-by-step approach

Step 1: Confirm what actually happened. Verify the dose given and the date of the prior injection using pharmacy or clinic records. Determine whether this was one extra dose, two doses at one visit, or an early re-dose.

Step 2: Assess the patient clinically. Check vital signs, examine the injection site, and obtain a baseline lipid panel, hepatic panel (ALT, AST, bilirubin), and creatinine. Add creatine kinase if the patient reports myalgia and is also on a statin.

Step 3: Do not attempt pharmacologic reversal. There is no antidote. Inclisiran already inside hepatocyte RISC complexes cannot be removed by dialysis or by any other means available to date. The circulating drug clears on its own within roughly one to two days given its short plasma half-life.

Step 4: Recheck labs at four to six weeks. This window is a reasonable estimate of when LDL-C effect and any liver enzyme change would be most apparent, based on the general pharmacodynamic timeline of the drug. If LDL-C is very low and the patient is asymptomatic, most clinicians would not intervene. If ALT rises above three times the upper limit of normal, repeat testing in two weeks and consider holding the next scheduled dose until it normalizes.

Step 5: Adjust the next scheduled dose. If a full extra dose was given, consider delaying the next planned injection, guided by a follow-up LDL-C level, to avoid stacking pharmacodynamic effects beyond what is clinically useful.

Step 6: Report the error. File a MedWatch report (FDA Form 3500) for any dosing error involving an unapproved regimen, whether or not the patient was harmed. This supports pharmacovigilance signal detection over time.

For urgent questions, contact the American Association of Poison Control Centers at 1-800-222-1222, available 24 hours a day, or the prescribing clinician directly. If the patient has signs of a serious reaction, such as facial swelling, difficulty breathing, or significant hypotension, seek emergency care rather than waiting for outpatient follow-up.

How this compares with PCSK9 monoclonal antibodies

Evolocumab and alirocumab are self-injected every two to four weeks, and patients keep multiple doses at home. That creates more day-to-day opportunity for a patient-driven dosing error than inclisiran, where a clinician gives every dose. Large cardiovascular outcome trials of these monoclonal antibodies have reported very low achieved LDL-C levels in substantial numbers of patients without a clear associated safety signal, which offers indirect reassurance about the consequences of aggressive PCSK9 pathway suppression generally. This is background context, not a direct study of inclisiran overdose, and the specific trial-level numbers should be checked against the primary publications before being cited precisely.

Special populations

Hepatic impairment. Patients with mild hepatic impairment have shown pharmacokinetics and LDL-C response similar to patients without liver disease in available data. Inclisiran is not recommended in moderate to severe hepatic impairment, and there is essentially no safety data in that population. An excess dose in a patient with unrecognized advanced liver disease is an unstudied scenario; check liver function before and after.

Pediatric use. Inclisiran is not approved under age 18. A trial in adolescents aged 12 to 17 with heterozygous familial hypercholesterolemia (ORION-16, NCT04652726) is registered on ClinicalTrials.gov; readers should check the current status and any published results directly on that registry rather than assuming a completed safety readout. An accidental pediatric exposure should be managed supportively, with pediatric specialist involvement if liver enzymes change.

Pregnancy. Inclisiran is not recommended in pregnancy because of insufficient human data. Cholesterol is needed for fetal development, so an excess dose during pregnancy raising the degree or duration of LDL-C suppression is a reasonable concern even without direct evidence of harm. Maternal-fetal medicine input is appropriate.

Concurrent statin or ezetimibe use. Most inclisiran patients are also on a statin. An extra dose on top of high-intensity statin therapy could push LDL-C very low. Available PCSK9-pathway data do not show harm at very low LDL-C, but the statin should not be stopped reflexively; monitor and decide based on the patient's overall risk and lipid trend.

What is established, what is plausible, and what is not established

Established: Inclisiran is given only by a healthcare professional in a fixed 284 mg dose, which structurally limits overdose opportunity compared with self-administered lipid-lowering drugs. The FDA label states there is no specific antidote and that overdose management is supportive. The drug's mechanism means plasma clearance is fast but the LDL-lowering effect persists for months regardless.

Plausible but not confirmed by a dedicated overdose study: That an extra or early dose produces mainly a deeper and longer LDL-C reduction plus more injection-site reaction, without hepatotoxicity or nephrotoxicity, based on extrapolation from dose-ranging and extension data rather than from a study designed to capture overdose.

Not established: Exact percentage figures for LDL-C reduction, injection-site reaction rates, or liver enzyme changes at supratherapeutic exposure. These numbers appear in secondary summaries of the ORION program but were not independently verified against primary trial publications for this article, and should not be treated as precise without that check. Outcomes in pregnancy, in moderate-to-severe hepatic impairment, and in children are essentially unstudied.

Decision framework: what to do when an inclisiran dosing error is reported

This table is a starting framework for structuring a response, not a substitute for individualized clinical judgment, and it does not replace consultation with the prescribing physician or a poison control center.